Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02983799 · ClinicalTrials.gov registry record · Phase 2
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
A Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT02983799: Completed Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, sponsored by AstraZeneca.
NCT02983799 is a Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity that has completed, run by AstraZeneca. The registered enrollment target is 272 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02983799, a Phase 2 study of Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at least 1 prior line of platinum-based chemotherapy.
Primary Outcome
To determine the clinical effectiveness of olaparib treatment in each of 4 cohorts assessed using ORR according to RECIST v1.1 criteria (Investigator determined)
Conditions Studied
Interventions
- DRUG OLAPARIB
Study Locations (20)
New Jersey
- Research Site - Berkeley Heights
- Research Site - Hackensack
- Research Site - Newark
- Research Site - Teaneck
California
- Research Site - La Jolla
- Research Site - Los Angeles
Connecticut
- Research Site - Hartford
- Research Site - New Haven
Michigan
- Research Site - Detroit
- Research Site - Detroit
Minnesota
- Research Site - Minneapolis
- Research Site - Saint Paul
Alaska
- Research Site - Anchorage
Colorado
- Research Site - Aurora
Delaware
- Research Site - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2020-12-03 |
| Phase | Phase 2 |
What the finished NCT02983799 record still lists
NCT02983799 is an interventional study that assigns participants to a tested intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher).
The record links to 1 condition, with Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity appearing as the primary indexed condition, and to 1 intervention - of which OLAPARIB is the first listed.
NCT02983799 names 20 study sites across 13 states, led by New Jersey, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02983799 about?
NCT02983799 is a clinical study titled "Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status". This is a non-randomized, open-label study to assess olaparib tablets as a treatment for subjects with different homologous recombination deficiency (HRD) tumor status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrioid ovarian cancer. Subjects should have received at...
What is the current status of trial NCT02983799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2016-12-22. Estimated completion is 2020-12-03.
What conditions does trial NCT02983799 study?
This clinical trial studies the following conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity.
What interventions are being tested in trial NCT02983799?
The interventions under investigation include: OLAPARIB (DRUG).
Who is sponsoring clinical trial NCT02983799?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02983799 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02983799's enrollment target sits among peer trials
272 204th of 2000 higher than 1,796 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI